Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systems Biology of MVA-BN-Filo and Ad26.ZEBOV in Healthy Volunteers
NCT02891980Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2017
- Primary completion
- Mar 2019
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zabdeno and Mvabea in Ebola Virus Disease (EVD) and Marburg virus disease (MVD) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Differential expression from baseline in mRNA at Day 546, Serious Adverse Events and 3 more. Started Mar 2017; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola Virus Disease (EVD)Marburg virus disease (MVD)
Beyond the preview
Go deeper on NCT02891980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891980.